TraceLink announces results from FDA DSCSA Pilot Program23 Jun 2020
Key findings demonstrate the value of network solutions to secure and digitalize the pharmaceutical supply chain.
TraceLink, a digital platform company for the life science supply chain, has announced results from its pilot for the FDA Pilot Project Program under the Drug Supply Chain Security Act (DSCSA).
The TraceLink pilot focused on two workstreams: digital recalls across a supply network; and an interoperable blockchain network solution. The pilots included 22 participating companies from pharmaceutical manufacturers, wholesale distributors, third-party logistic providers, hospitals and retail pharmacies.
The pilot employed early-stage technology solutions to address pharmaceutical supply chain challenges and establish a deep understanding of how technology can realistically ease those burdens. Both workstreams were designed to create a vision and blueprint for the data, operational processes, business systems, and network connections required to realize DSCSA 2023 compliance and to digitalize pharmaceutical drug recalls.“The results from our pilot gleaned significant insights that will help solve different, but equally important, challenges that the pharmaceutical industry will continue to face until DSCSA 2023, with both workstreams highlighting the value of a digital network in improving processes and efficiencies within the supply chain,” said Shabbir Dahod, president and CEO of TraceLink. Dahod advised that now is the time for the industry to begin acting on some of these pilot findings, including improving processes and allowing better visibility, agility, and collaboration among supply chain stakeholders.”
Product Recalls Workstream: Digital Recalls Across the Supply Network
Pilot participants in TraceLink’s digital recalls workstream explored ways to solve challenges associated with today’s product recall process, plagued by disjointed systems, manual processes, and long delays in communication between supply chain stakeholders including leveraging TraceLink’s emerging digital recalls network solution.Joe Maki, pilot participant and senior director of pharmacy operations, Novant Health noted that this workstream further demonstrated how inefficient the current industry process is in executing product recalls. “The learnings emphasized how a digital recalls platform could vastly improve the execution of recalls by eliminating manual, error-prone processes and would also help to better define accountability among supply chain stakeholders with improved collaboration, ultimately reducing the risk to patients by getting recalled product off the market faster.”
The recalls workstream identified a strong opportunity to improve the drug recalls process with the integration of bi-directional communications and digital recall notifications to bolster response times across the execution phase, which would require a collaborative effort among industry stakeholders to create an effective blueprint and roadmap for adoption.
2023 Traceability Workstream, TraceLink’s Interoperable Blockchain Network Solution with Trace Histories
By 2023, DSCSA will require an electronic, interoperable system by 2023 to identify and trace certain prescription drugs. TraceLink’s blockchain workstream evaluated existing information, processes and systems to determine if and how they can meet 2023 DSCSA requirements.
Pilot members analysed the strengths and weaknesses of proposed electronic network models for DSCSA 2023, including the evaluation of TraceLink’s interoperable blockchain solution to determine whether blockchain-centric and/or non-blockchain approaches may be effective.
Business processes related to product traceability are extremely complex due to the diversity of the pharmaceutical supply chain. The findings identified blockchain as one piece of a larger technology solution that could support product traceability under the DSCSA 2023 guidelines. However, the pilot strongly indicates that reliance on any single technology or sole platform to meet the DSCSA 2023 guidelines is extremely unlikely.
SGS joins with Biophytis to launch international trial of COVID-19 related respiratory failure treatment
7 Jul 2020
The CRO will undertake this clinical trial at multiple sites worldwide, starting at the AZ Sint Maarten hospital in Mechelen, Belgium.Read more
Regeneron wins $450 million US government manufacturing agreement for anti-viral antibody cocktail
7 Jul 2020
The company began scaling up manufacturing of REGN-COV2 at business risk earlier this year to ensure the immediate availability of the product if clinical trials prove successful.Read more
Croda bolsters position in life sciences with the acquisition of Avanti Polar Lipids
6 Jul 2020
The transaction will more than double Croda’s R&D capability in drug delivery.Read more
Rentschler Biopharma and Vetter team up to simplify processes
6 Jul 2020
Companies agree that the key to tackling drug development complexity is collaboration.Read more
Cambrex increases flexible manufacturing capacity at Karlskoga, Sweden facility
6 Jul 2020
An investment of $3.6 million will cover the installation of a new production line to keep pace with continued growth in commercial-scale API manufacturing.Read more
iNova Pharmaceuticals announces the launch of iPitch 2020
3 Jul 2020
Following on from the success of the inaugural iPitch launch in 2019, iNova Pharmaceuticals is delighted to announce the launch of a new round of iPitch challenges for 2020.Read more
Ajinomoto introduces fast track platform for drug product manufacturing
30 Jun 2020
AJILITY is designed to speed novel or existing therapeutics from development to manufacturing and into the clinic.Read more
CPhI Worldwide to transform into Festival of Pharma digital experience
30 Jun 2020
The 10-day event will feature an interactive digital marketplace for sourcing products and services, enhanced matchmaking for connecting with new and existing partners, and world-renowned speakers.Read more
Catalent expands beauty and plant-based consumer health softgel capabilities
30 Jun 2020
Two company sites - one in Canada, the other in Brazil - receive new softgel encapsulation lines to service local customer demand.Read more
Stevanato Group pledges to provide glass vials for potential COVID-19 vaccines
29 Jun 2020
The company agrees to provide CEPI with 100 million glass vials, which can store 20 doses per vial (2 billion doses in total).Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation